S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
Log in

Adial Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ADIL)

$1.55
+0.04 (+2.65 %)
(As of 11/19/2019 04:00 PM ET)
Today's Range
$1.51
Now: $1.55
$1.61
50-Day Range
$1.41
MA: $1.54
$1.73
52-Week Range
$1.26
Now: $1.55
$9.44
Volume17,100 shs
Average Volume192,758 shs
Market Capitalization$15.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADIL
CUSIPN/A
Phone434-422-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.68 per share

Profitability

Net Income$-11,630,000.00

Miscellaneous

Employees3
Market Cap$15.99 million
Next Earnings Date11/20/2019 (Estimated)
OptionableNot Optionable

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.


Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 20th 2019. View Earnings Estimates for Adial Pharmaceuticals.

What price target have analysts set for ADIL?

2 analysts have issued 1 year target prices for Adial Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 222.6% from the stock's current price. View Analyst Price Targets for Adial Pharmaceuticals.

What is the consensus analysts' recommendation for Adial Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.

What are Wall Street analysts saying about Adial Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adial Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE. " (6/11/2019)
  • 2. Maxim Group analysts commented, "Adial announced that the company is expanding its activities around its lead asset AD04, beyond alcohol use disorder (AUD) to now include potential use in patients with opioid use disorder (OUD)." (12/13/2018)

Has Adial Pharmaceuticals been receiving favorable news coverage?

Headlines about ADIL stock have been trending very negative on Tuesday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Adial Pharmaceuticals earned a news impact score of -3.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Adial Pharmaceuticals.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a decline in short interest in October. As of October 31st, there was short interest totalling 44,900 shares, a decline of 9.7% from the September 30th total of 49,700 shares. Based on an average daily trading volume, of 41,500 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.7% of the shares of the stock are sold short. View Adial Pharmaceuticals' Current Options Chain.

Who are some of Adial Pharmaceuticals' key competitors?

What other stocks do shareholders of Adial Pharmaceuticals own?

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the folowing people:
  • Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
  • Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)
  • Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)
  • Ms. Monika Z. Rogozinska, Chief Devel. Officer
  • Mr. Alex Lugovoy, Head of Strategy

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $1.55.

How big of a company is Adial Pharmaceuticals?

Adial Pharmaceuticals has a market capitalization of $15.99 million. Adial Pharmaceuticals employs 3 workers across the globe.View Additional Information About Adial Pharmaceuticals.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is http://www.adialpharma.com/.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]


MarketBeat Community Rating for Adial Pharmaceuticals (NASDAQ ADIL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel